Dan Kemp, Wugen CEO

A stealthy start­up is lever­ag­ing nat­ur­al killer cells with 'mem­o­ry-like' abil­i­ties to go af­ter blood can­cer and be­yond

The promise of next-gen, “off-the-shelf” cell ther­a­pies have thor­ough­ly en­tranced bio­phar­ma with the promise of low­er­ing man­u­fac­tur­ing costs and po­ten­tial­ly chal­leng­ing dom­i­nant check­point in­hibitors. But …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.